Table 1

Baseline characteristics of patients with RA

MTX continue
(n=156)
MTX hold
(n=160)
Female (%)129 (82.7%)140 (87.5%)
Age, years52.2±9.553.7±10.3
Duration of RA, years6.8±6.56.9±6.2
RF positivity120/154 (77.9%)132/157 (84.1%)
ACPA positivity105/121 (86.8%)111/135 (82.2%)
DAS28-CRP2.2±0.92.3±1.1
Treatment
 GC82 (52.6%)74 (46.3%)
 Mean GC dose, mg/day1.8±2.11.7±2.1
 MTX156 (100%)160 (100%)
 MTX dose, mg/week13.3±3.413.1±3.2
 Sulfasalazine8 (5.1%)10 (6.3%)
 Hydroxychloroquine35 (22.4%)31 (19.4%)
 Leflunomide33 (21.2%)37 (23.1%)
 Tacrolimus2 (1.3%)2 (1.3%)
Biological DMARDs
 TNF inhibitor11 (7.1%)13 (8.1%)
 Abatacept1 (0.6%)6 (3.8%)
 Tocilizumab4 (2.6%)7 (4.4%)
 Rituximab1 (0.6%)1 (0.6%)
 Tofacitinib0 (0%)1 (0.6%)
  • Numbers are in n (%) or mean±SD.

  • ACPA, anticyclic citrullinated peptide-antibody; BAFF, B-cell activation factor; CRP, C reactive protein; DAS28, Disease Activity Score in 28 joints; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumour necrosis factor.